Mumbai, Maharashtra
Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe is once again in the spotlight. Following strong criticism from the Bombay High Court over the FDA’s alleged “overzealous” and “authoritarian” approach, Mundhe has defended his actions and administrative style. He said that he is not God, but Tukaram Mundhe, and that he is simply performing his duties as a public servant.
The matter concerns the drug sale licence of the “carry and forwarding” unit of Cipla Pharma and Life Sciences Limited in Pune. Following the High Court’s strong observations, the FDA has decided to withdraw its order cancelling the unit’s licence. The court had found the FDA’s action to be contrary to the principles of natural justice.
“I Am Not God, I Am Tukaram Mundhe”
During a press conference, journalists referred to the High Court’s observations and asked Tukaram Mundhe whether the FDA had acted with excessive haste.
In response, Mundhe said that he is not God.
Mundhe stated that he is “Tukaram Mundhe” and is carrying out his responsibilities as a public servant. He said that he has no doubt or ambiguity about the work he is doing.
However, the FDA Commissioner also said that if there was any mistake or procedural error in the department’s action, and the court has brought it to light, the matter would be seriously considered. He said that the department is prepared to address such shortcomings and make the necessary corrections.
High Court Expresses Displeasure Over FDA Action
During the hearing, the Bombay High Court expressed strong displeasure with the FDA’s approach. The court reportedly described the department’s action as excessively harsh and observed that shutting down a business or cancelling its licence over minor shortcomings may not be appropriate.
To illustrate the severity of the action, the court made a sharp observation, comparing it to “using a sword to kill a mosquito.” The court emphasized that authorities should adopt a practical approach while enforcing regulations and that the harshest possible action may not be justified in every case.
The court also raised questions about whether the principles of natural justice had been properly followed in the FDA’s action. Following the court’s observations, the department decided to withdraw its decision to cancel the licence of the Cipla unit.
Focus on Balancing Regulatory Action and Due Process
The High Court’s observations have brought renewed attention to the balance between regulatory enforcement and legal due process. The FDA’s responsibility is to ensure the quality and safety of medicines, but when action is taken against an establishment, it is equally important to follow the prescribed legal procedure and provide the concerned party with an opportunity to present its case.
Through his statement, Tukaram Mundhe has indicated that the department will not ignore the court’s observations. He said that wherever mistakes in the regulatory process are identified, corrective measures will be taken.
It will therefore be important to see how the FDA modifies its enforcement procedures in the coming period and how regulatory action in cases involving pharmaceutical businesses proceeds following the court’s concerns.
